Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192959 | 1.00 | ATM (0.46) | ATMTDP1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL14797548 | 0.89 | SMN1; SMN2 (0.50) | ALDH1A1MT-CO2PTGS2PTGS1SMN1; SMN2 | |
| SCHEMBL6210738 | 0.87 | NPSR1 (0.38) | ATMTDP1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL5676255 | 0.86 | TDP1 (0.44) | ATMTDP1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL10776718 | 0.85 | APP (0.56) | ATMTDP1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL25447155 | 0.84 | ATM (0.42) | ATMTDP1ALDH1A1AKR1C3AKR1C2 | |
| SCHEMBL5948033 | 0.84 | AKR1C3 (0.59) | ATMTDP1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL13172342 | 0.84 | ATM (0.50) | ATMTDP1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL30192831 | 0.84 | AKR1C3 (0.59) | ATMTDP1AKR1C3AKR1C2PTGS2 | |
| SCHEMBL5948037 | 0.84 | AKR1C3 (0.59) | ATMTDP1AKR1C3AKR1C2PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2880015-B1 | MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF | FOND ST ITALIANO TECNOLOGIA (IT) | 2017-09-27 | — | — | EP | disclosed |
| US-9630914-B2 | Multitarget FAAH and COX inhibitors and therapeutical uses thereof | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-04-25 | — | — | US | disclosed |
| US-20150203447-A1 | MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF | Fondazione Istituti Italiano di Tecnologia (IT) | 2015-07-23 | — | — | US | disclosed |
| EP-2880015-A1 | MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF | Fondazione Istituto Italiano Di Tecnologia (IT) | 2015-06-10 | — | — | EP | disclosed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| US-8937092-B2 | Aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-01-20 | — | — | US | disclosed |
| EP-2760835-A1 | ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-08-06 | — | — | EP | disclosed |
| US-8735426-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-05-27 | — | — | US | disclosed |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-03-28 | — | — | US | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| CN-1780821-A | Heterocyclic kinase inhibitors. | ABBOTT LAB (US) | 2006-05-31 | — | — | CN | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
| US-4710581-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1987-12-01 | — | — | US | disclosed |
| US-4581463-A | Nucleophilic substitution process combined with additional reaction steps | ETHYL CORPORATION (US) | 1986-04-08 | — | — | US | disclosed |
| EP-0077662-B1 | PREPARATION OF NITROARYLACETIC ACID ESTERS AND DERIVATIVES THEREOF | ETHYL CORPORATION (US) | 1985-10-02 | — | — | EP | disclosed |
| EP-0077662-A1 | Preparation of nitroarylacetic acid esters and derivatives thereof | ETHYL CORPORATION (US) | 1983-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203447-A1 | MULTITARGET FAAH AND COX INHIBITORS AND THERAPEUTICAL USES THEREOF | FAAH, FAAH2, CNR2 | ATM 4387/4885TDP1 2781/4885ALDH1A1 337/4885 |
| US-20130079377-A1 | Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands | TRPV1, TRPV3, TRPA1 | ATM 2756/4885TDP1 4706/4885ALDH1A1 2770/4885 |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | ATM 391/4885TDP1 1112/4885ALDH1A1 2391/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | ATM 336/4885TDP1 1384/4885ALDH1A1 3257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.